Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.52 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ACACB | O00763 | 2/20 | 0.48 |
| ▸ | ACACA | Q13085 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6642459 | 0.90 | KDM4E (0.58) | DRD2KDM1AMAOBKDM4EPKM | |
| SCHEMBL6637593 | 0.90 | KDM4E (0.58) | DRD2KDM1AMAOBKDM4EPKM | |
| SCHEMBL6637597 | 0.90 | KDM4E (0.58) | DRD2KDM1AMAOBKDM4EPKM | |
| SCHEMBL6638918 | 0.84 | ACACB (0.55) | DRD2KDM1AMAOBKDM4EPKM | |
| SCHEMBL6638926 | 0.84 | ACACB (0.55) | DRD2KDM1AMAOBKDM4EPKM | |
| SCHEMBL6638634 | 0.83 | KDM4E (0.56) | DRD2KDM1AMAOBKDM4EPKM | |
| SCHEMBL24011514 | 0.83 | KDM1A (0.61) | DRD2KDM1AMAOBKDM4EPKM | |
| SCHEMBL24512916 | 0.83 | KDM1A (0.61) | DRD2KDM1AMAOBKDM4EPKM | |
| SCHEMBL6641643 | 0.82 | MEN1 (0.49) | PKMKMT2ASMN1; SMN2 | |
| SCHEMBL25970123 | 0.81 | ACHE (0.61) | DRD2ACHEKMT2ARAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1250340-B1 | METHODS AND COMPOUNDS FOR INHIBITING MRP1 | LILLY CO ELI (US) | 2004-11-17 | — | — | EP | disclosed |
| US-20040176405-A1 | Methods and compounds for inhibitting MRP1 | KROIN JULIAN (US) | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176405-A1 | Methods and compounds for inhibitting MRP1 | ABCC1, ABCB11, ABCB1 | DRD2 4464/4885KDM1A 4351/4885MAOB 1898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.